Welcome to our dedicated page for FIVE BELOW SEC filings (Ticker: FIVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Five Below, Inc. filings document formal disclosures for a Nasdaq-listed specialty value retailer with common stock trading under the symbol FIVE. Its 8-K reports include results of operations and financial condition, Regulation FD outlook releases, press-release exhibits, and executive officer appointments, departures and compensation arrangements.
Proxy materials cover annual meeting procedures and shareholder voting matters for the company. The filing record also identifies the company’s registered common stock, exchange listing, corporate jurisdiction and recurring governance disclosures associated with its public-company reporting obligations.
Form 144 Notice of Proposed Sale filed by Five Below officer Eric M. Specter, indicating intent to sell 5,500 shares of common stock with an aggregate market value of $719,214.10. The sale is planned for execution on June 26, 2025 through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares to be sold were acquired through two restricted stock vestings under a registered plan:
- 5,416 shares acquired on March 28, 2019
- 84 shares acquired on March 07, 2019
The filing indicates that Specter has not sold any company securities in the past 3 months. As required by Rule 144, the seller has certified no knowledge of undisclosed material adverse information regarding Five Below's operations. The company currently has 55,058,005 shares outstanding.
Five Below, Inc. (FIVE) – Form 4 insider transaction filed 18-Jun-2025. Chief Information Officer Amit Jhunjhunwala sold a total of 1,700 common shares on 16-Jun-2025 at prices of $125.00 and $125.41. After the transactions, his direct ownership decreased from 27,590 shares to 25,890 shares, a reduction of roughly 6% of his personal stake. No derivative transactions or 10b5-1 plan indications were disclosed. The filing was signed by attorney-in-fact Ronald J. Masciantonio.